DOI: 10.36347/sjmcr.2015.v03i08.014

Pages: 695-697

It is unfortunate that many patients with essential thrombocythemia are diagnosed during a thrombotic event (sometimes with disabling consequences) and are not detected by regular screening actions made by family physicians. We present the case of a female patient who developed ischemic stroke, during which a thrombocytosis was detected. The investigations led to the diagnosis of essential thrombocythemia with JAK2V617F mutation present in heterozygous version. The treatment with hydroxycarbamide produced liver cytolysis and that with anagrelide - blood pressure increase. Combining the two drugs allowed to reduce the doses and to obtain the disappearance of side effects. The role of chronic inflammation and therapeutic possibilities in essential thrombocythemia are discussed. The long time compliance of patient to active monitoring and treatment is essential for longue time survival without complications.